ZVRA Stock Hub: MIPLYFFA, SSIEM and EU re-examination

01 Q2 confirms MIPLYFFA momentum, positive operating economics and a larger cash position

Q2 revenue $39.7M included $30.2M MIPLYFFA and $9M global EAP reimbursement. Fourteen new prescription forms brought cumulative U.S. forms to 184; these are not all active paid patients. Global EAP enrollment was 132. Q2 operating income $16.777M and net income $8.752M were positive; cash and investments reached $260.179M. The European re-examination has been requested, with no outcome confirmed.

02 Q2 2026 Deep Dive: Better U.S. Launch Evidence, but Europe Still Defines the Regulatory Skew

The Q2 print materially strengthens the evidence that MIPLYFFA has become a commercially meaningful U.S. rare-disease franchise. Total net revenue was $39.663 million, compared with $36.220 million in Q1 and $25.881 million in Q2 2025. MIPLYFFA contributed $30.2 million, up 22.8% sequentially and approximately 40.5% year over year. That acceleration is more informative than total-company growth because it comes from the asset that now carries most of Zevra’s recurring value after the SDX divestiture.

The patient funnel also advanced, but it should be interpreted carefully. Fourteen prescription enrollment forms were received during Q2, versus nine during Q1, taking the cumulative count to 184. A prescription enrollment form begins the access and benefits process; it does not equal a dispensed prescription, an active reimbursed patient or durable persistence. Payer access remained unchanged at 69% of covered lives, so Q2’s revenue improvement appears to reflect stronger execution within an already established access footprint rather than a fresh coverage step-up.

The European read-through is mixed. Global EAP enrollment increased by ten patients to 132, confirming that the program remained active through June 30. Net EAP reimbursement nevertheless fell 11.8% sequentially to $9.0 million. Patient growth and revenue do not move one-for-one because country mix, collection timing, reimbursement terms, gross-to-net adjustments and clawback accounting can differ. The decline does not prove that access is contracting, but it reinforces why EAP revenue should not be capitalized as a fixed annuity while the CHMP re-examination is pending.

EPS quality screen: Q2 GAAP earnings are more representative of current operations than either Q1 2026, which included the $43.3 million SDX-sale gain and debt-payoff effects, or Q2 2025, which included the PRV sale, impairment and inventory charges. Even so, the $6.4 million non-cash fair-value charge makes GAAP net income lower than the operating result. The cleanest recurring signal is the $16.8 million operating profit, not a mechanical annualization of either GAAP or adjusted EPS.

Evidence posture: the earnings release, Form 8-K and Q2 Form 10-Q were reviewed. The filing confirms $23.2 million of positive operating cash flow for the first six months of 2026, an $18.6 million aggregate EAP clawback liability and no ATM sales through June 30. No official text transcript was available in the retrieved source set, so this coverage does not attribute call-only statements from unofficial transcripts.

03 Executive Summary: A Strong U.S. Launch Meets a Serious European Evidence Challenge

Zevra is a commercial rare-disease company centered on MIPLYFFA, with celiprolol in Phase 3 and a small OLPRUVA business. The SDX portfolio was sold to Commave in March. September 4 price and July shares imply $736.36M basic value; June liquidity is a dated balance, not a guaranteed liquidation value. CHMP re-examination is already requested. U.S. growth and the European evidence dispute remain separate drivers.

04 The Merlintrader View: Watchlist-Quality Fundamentals, but Europe Is No Longer a Clean Upside Option

Zevra has enough operating substance for a full Stock Hub because its investment case contains four separate analytical layers: a marketed rare-disease franchise, a disputed cross-regulatory evidence package, a second late-stage clinical program and an unusually liquid balance sheet. That is more durable than a one-day news article. The next reporting cycle should update sales, enrollment, EAP economics and the re-examination strategy.

The positive side is straightforward. U.S. MIPLYFFA revenue reached $30.2 million in Q2, payer coverage remained 69% of covered lives, the company reported 184 prescription enrollment forms since launch, and management has a $260.2 million liquidity cushion. An enrollment form starts the benefits-investigation process; it is not the same as an active, reimbursed patient. MIPLYFFA also received an Orange Book patent listing that the company says can protect the franchise until November 2041, subject to the usual caveat that patent listing is not the same as guaranteed freedom from challenge. Celiprolol addresses a severe rare disease with no FDA-approved disease-specific therapy and is being studied under a Special Protocol Assessment.

The caution side is equally important. MIPLYFFA is still a concentrated launch in an ultra-rare population. The easy-to-find or pent-up patient cohort can make early rare-disease launches look stronger than their steady-state new-patient flow. Europe cannot now be valued as a routine label expansion. The re-examination may uphold the refusal, and no new data can simply be added during that procedure. Celiprolol is event-driven and had only three confirmed qualifying events at June 30, so its timing remains difficult to forecast. Finally, the company has an unused $75 million ATM and broad shelf capacity even though near-term financing need appears low.

Research posture: Q2 improves the U.S. launch and balance-sheet evidence enough to strengthen the operating side of the ZVRA thesis. It does not repair the European scientific-regulatory dispute. The next conviction step requires sustained MIPLYFFA growth beyond the early launch cohort, transparent EAP economics, credible re-examination arguments and specific FDA feedback on celiprolol.

05 Fast Facts and Current Market Snapshot

Marketstack September 4 close $12.40. July 31 SEC shares 59,383,781 imply basic equity value $736.36M. Finviz $736.31M uses a slightly different share/rounding base. June shares 59,341,906; the June company-defined diluted count is 69,298,105, including awards and warrants, not the GAAP diluted EPS denominator. Finviz September 7: float 58.62M, short float 11.04%, short ratio 4.45, institutions 76.51%, insiders 1.28%. These dated aggregates may overlap and lag underlying filings.

06 Catalyst Map: Hard Dates, Regulatory Windows and Event-Driven Milestones

Confirmed next events: Cantor September 9 at 09:10 ET; Morgan Stanley September 14 at 17:35 ET; H.C. Wainwright September 15 at 10:00 ET. These investor presentations are separate from the CHMP re-examination, requested by the August 5 disclosure but without a confirmed outcome date. DiSCOVER remains event-driven: 28 qualifying events for interim and 46 for final analysis. Company plans H2 FDA dialogue on acceleration; no accelerated timeline is agreed.

IR · September events

07 Company Overview: From KemPharm to a Focused Rare-Disease Commercial Company

Zevra began as KemPharm, a company known for prodrug technology and the serdexmethylphenidate, or SDX, portfolio. The strategic identity changed in May 2022 when the company acquired substantially all assets and operations related to arimoclomol from Orphazyme for $12.8 million in cash while assuming an estimated $5.2 million EAP-related reserve liability. That transaction placed a late-stage rare-disease asset at the center of the company.

KemPharm changed its name to Zevra Therapeutics in February 2023. Later that year, Zevra acquired Acer Therapeutics, adding OLPRUVA, celiprolol and commercial infrastructure. The Acer deal transformed Zevra into a commercial-stage rare-disease company before MIPLYFFA was approved, but it also brought contingent value rights and an asset, OLPRUVA, whose commercial contribution has remained small.

The most important transformation occurred in September 2024, when FDA approved MIPLYFFA. Commercial dispensing began in November 2024. Zevra then monetized the rare pediatric disease priority review voucher received with approval for $150 million, producing $148.3 million in net proceeds in April 2025. That transaction, combined with growing product revenue, strengthened the balance sheet.

In March 2026, Zevra completed another strategic reset by selling the entire SDX portfolio, including AZSTARYS and KP1077, to Commave for $50 million and settling related litigation. The sale simplified the company and removed future royalties and milestones that had once been part of the story. Zevra is now centered on MIPLYFFA, celiprolol and future business development, with OLPRUVA as a secondary commercial asset.

08 Pipeline and Product Map: What Zevra Actually Owns Today

09 MIPLYFFA in the United States: The Commercial Foundation Is Already Visible

MIPLYFFA is an oral capsule taken three times daily and is approved in combination with miglustat for the treatment of neurological manifestations of NPC in adults and children aged two years and older. FDA approved it on September 20, 2024, making it the first FDA-approved treatment for NPC. Four days later, FDA approved IntraBio’s AQNEURSA, a stand-alone levacetylleucine therapy for adults and pediatric patients weighing at least 15 kilograms. The two products therefore entered the market at nearly the same time but with different labels, evidence packages and positioning.

The pivotal MIPLYFFA evidence came from a randomized, double-blind, placebo-controlled study involving 50 children and adolescents aged two to 18 years. FDA’s label-relevant population included 39 patients receiving concomitant miglustat. The main measure was change in a five-domain NPC Clinical Severity Scale covering ambulation, swallowing, cognition, speech and fine motor skills. FDA accepted the evidence in the combination-with-miglustat population, while EMA later concluded that the overall efficacy case was not sufficiently robust. This difference in regulatory interpretation is now the defining scientific issue for the company.

Commercial execution has been strong enough to make MIPLYFFA a real franchise. Zevra reported $87.4 million of MIPLYFFA U.S. net revenue in 2025. In Q1 2026, net sales reached $24.6 million; in Q2 they increased to $30.2 million, up 22.8% sequentially and approximately 40.5% from Q2 2025. The company received 14 new prescription enrollment forms during Q2 and 184 since launch, while payer coverage remained 69% of covered lives. Those forms initiate benefits investigation and should not be equated one-for-one with active or paying patients. Management estimates that roughly 900 people in the United States live with NPC, of whom approximately 300 to 350 are diagnosed or treated.

Those prevalence estimates are company framing, not a guaranteed commercial denominator. The investable question is not how many patients theoretically live with NPC; it is how many are diagnosed, clinically appropriate, reimbursed, initiated and persistent on therapy. In ultra-rare disease, patient identification can create substantial growth, but every lost patient or delayed authorization matters. Q2 results should therefore be read through prescription forms, covered lives, starts, persistence and gross-to-net quality rather than product revenue alone.

10 Mechanism, Label and Safety: The Details That Shape the Commercial Asset

Arimoclomol increases activation of the transcription factors TFEB and TFE3, which upregulate coordinated lysosomal expression and regulation, or CLEAR, genes. It has also been shown to reduce unesterified cholesterol in lysosomes of human NPC fibroblasts. FDA’s prescribing information is appropriately cautious: the clinical significance of those mechanistic findings is not fully understood. For investors, mechanism supports the biological narrative, but the label and clinical outcomes determine the economic asset.

The approved dose is weight-based and administered three times daily. The combination requirement with miglustat is important because it affects treatment burden, payer management and the comparison with AQNEURSA, which is approved as a stand-alone therapy. MIPLYFFA may still be used within a broader multi-drug treatment approach, but investors should not treat the NPC market as a simple winner-take-all opportunity.

The label includes warnings for hypersensitivity reactions, embryofetal toxicity and increased creatinine without an apparent effect on glomerular function. In the pivotal trial, hypersensitivity reactions including urticaria and angioedema were reported; the most common adverse reactions among MIPLYFFA-treated patients also receiving miglustat included upper respiratory tract infection, diarrhea and decreased weight. These risks do not negate the launch, but they are part of prescriber education and patient monitoring.

Pricing also requires care. Public launch reports indicated an annual list-price range that varied substantially by patient weight, with the highest dose producing a figure above $1 million per year and analysts estimating a much lower average net price. List price should never be treated as realized revenue. The useful commercial variables are net sales per treated patient, gross-to-net deductions, coverage, persistence and the mix of patient weights and access routes.

11 The EMA Refusal: Why Europe Reached a Different Conclusion From FDA

The CHMP opinion adopted on July 23, 2026, recommended refusal of Meplyffa for use with miglustat in patients aged two years and older with NPC. EMA’s explanation went beyond a narrow administrative objection. The committee concluded that efficacy had not been sufficiently demonstrated. It identified uncertainties arising from the way data were handled and results analysed, questioned the reliability and robustness of the findings, and noted that no benefit was observed for ambulation and cognition.

The miglustat subgroup is central. Zevra’s U.S. label is specifically for MIPLYFFA in combination with miglustat, and the subgroup taking miglustat showed a treatment effect favoring arimoclomol. CHMP nevertheless concluded that this finding was not robust because efficacy had not been demonstrated in the overall randomized population. That is a classic regulatory fault line: whether a clinically relevant subgroup can carry an application when the full population is less convincing and whether the analytical pathway adequately supports the subgroup conclusion.

FDA and EMA can reach different conclusions because they are not required to weigh the same evidence in exactly the same way. FDA’s approval does not make the EMA opinion irrational, and the EMA refusal does not automatically invalidate the U.S. label. Each agency evaluates benefit-risk, statistical robustness, clinical relevance and the proposed label under its own review framework. The resulting divergence creates both scientific debate and valuation uncertainty.

The refusal also matters commercially before any final Commission decision. Zevra said it would continue expanded-access programs pending discussions with national authorities. Those programs are country-specific, and continued access cannot be assumed uniformly. EAP reimbursement was $10.2 million net in Q1 2026 and $9.0 million in Q2, so any reduction in patients, reimbursement or program duration could affect reported revenue before a formal European commercial launch is even possible.

EMA’s current application name is Meplyffa, distinct from the U.S. MIPLYFFA brand and the older 2022 withdrawn application. July 23 negative opinion concerned robustness of efficacy analyses and lack of demonstrated benefit on ambulation/cognition. Zevra states re-examination has been requested; no reversal or EU approval is confirmed as of September 7.

EMA · Meplyffa

12 Re-examination: A Real Route, but Not a New Trial in Disguise

Zevra confirmed that re-examination was requested in the August 5 Q2 disclosure. The procedure reassesses the grounds of the existing opinion; it is not a new trial or an approval. No final opinion date or reversal is confirmed. The current EMA page retains the July 23 negative opinion, while the company filing confirms the procedural request.

13 Expanded Access: Clinically Important and Financially Material

Zevra’s global expanded-access programs provide arimoclomol to eligible patients outside ordinary commercial availability. At June 30, 2026, the company reported 132 patients enrolled across the global EAP, ten more than at March 31, and $9.0 million of Q2 net reimbursement. That revenue was net of $4.3 million in clawback and other adjustments. The aggregate clawback liability increased to $18.6 million at June 30 from $16.9 million at March 31.

The accounting matters because gross reimbursement is not the same as durable net revenue. EAP receipts can be affected by country rules, timing, clawbacks, price negotiations and what happens after a regulatory decision. Q1’s $10.2 million represented about 28% of total company net revenue, so the EAP is no longer a minor footnote.

Following the CHMP opinion, EMA said Zevra informed the agency that ongoing compassionate-use programs would continue pending discussions with national authorities that granted access. That wording supports continued treatment in the immediate period but does not guarantee an unchanged patient count, price or duration across Europe. Each national authority can matter.

Q2 answered the first question positively: enrollment increased. It did not eliminate the other three questions—whether new patients can continue entering, how reimbursement terms evolve and whether clawback liabilities keep rising. A stable EAP would cushion the European setback while re-examination proceeds. A contraction would make the refusal more immediately visible in the income statement.

August 25 SSIEM update: U.S. observational cohorts had four-year data for 20 patients versus 78 at year one. German compassionate use covered 48 people, mean exposure three years, up to eight; 46 also received miglustat. Reported stabilization does not establish a controlled causal effect; small later cohorts and attrition matter. These findings do not reverse the CHMP opinion.

SSIEM · company data

14 MIPLYFFA Lifecycle Management: Patent Protection and Infant Data

On June 8, 2026, Zevra announced the Orange Book listing of U.S. Patent No. 11,707,456 for MIPLYFFA. The patent expires on November 19, 2041. The company also has a separate patent-term extension application pending for U.S. Patent No. 11,045,460, which currently expires in 2029. The listing materially improved the company’s public IP narrative and contributed to several analyst target increases before the CHMP news.

Patent protection should be treated carefully. An Orange Book listing establishes a formal patent position associated with the approved drug and can shape generic challenge timing, but it does not guarantee that every claim will survive litigation or block all forms of competition until 2041. Regulatory exclusivity and patent protection are also different legal concepts. Investors should value the estate as an advantage while leaving room for challenge risk.

On June 23, Zevra announced publication of an open-label pediatric substudy involving five children aged 12 to under 24 months at enrollment. Arimoclomol was used with concomitant miglustat for up to 36 months. The company reported that treatment was generally well tolerated, with no new safety signals, and that pharmacokinetics were consistent with older pediatric populations. Developmental outcomes varied, which Zevra attributed to disease heterogeneity.

The substudy is useful scientific evidence but should not be promoted as if it were a registrational program. Five patients in an open-label design cannot establish efficacy or guarantee a label expansion below age two. Zevra has described the data as supporting exploration of earlier treatment, but it had not announced a formal supplemental NDA timetable as of July 24. The correct valuation treatment is modest lifecycle optionality.

15 Celiprolol and VEDS: The Second Core Asset

Vascular Ehlers-Danlos syndrome is a severe inherited connective-tissue disorder caused by pathogenic variants in COL3A1. Defective type III collagen weakens arteries and hollow organs, creating risks of arterial aneurysm, dissection and rupture, uterine rupture, intestinal rupture and sudden death. Zevra estimates that roughly 7,500 diagnosed people in the United States live with VEDS and that about 95% of diagnoses are genetically confirmed. Those figures are company estimates and should be interpreted as a disease-awareness framework rather than a guaranteed commercial market.

Celiprolol is a selective adrenergic modulator believed to reduce mechanical stress on arterial walls. It is used in some European countries for VEDS but is not FDA approved for the disease. A prior U.S. application received a complete response letter because FDA required an adequate and well-controlled trial demonstrating reduction in clinical events. That history explains why the current program is event-driven and why retrospective or European observational evidence alone is not sufficient for U.S. approval.

Celiprolol has U.S. Orphan Drug Designation and Breakthrough Therapy Designation. DiSCOVER is being conducted under a Special Protocol Assessment, which indicates FDA agreement on key protocol features but does not guarantee approval or a positive result. The scientific and commercial opportunity is substantial because no FDA-approved disease-specific pharmacologic therapy exists for VEDS, but the trial must demonstrate a clinically meaningful reduction in serious events.

Zevra has described prior evidence including the randomized BBEST study and long-term European cohorts, with annual major vascular event rates around 5% on celiprolol versus roughly 12% untreated in company materials. Cross-study and observational comparisons are inherently weaker than the ongoing placebo-controlled Phase 3 trial. The market should therefore treat prior data as rationale, not as a substitute for DiSCOVER.

16 DiSCOVER Phase 3: Design, Enrollment and the Timing Problem

DiSCOVER, ClinicalTrials.gov identifier NCT05432466, is a prospective, randomized, double-blind, placebo-controlled Phase 3 study in genetically confirmed COL3A1-positive VEDS patients aged 15 to 64 years. The decentralized design is intended to enroll approximately 150 patients. One hundred receive celiprolol titrated to 200 mg twice daily, while 50 receive placebo.

The primary endpoint is based on fatal or non-fatal qualifying clinical events, adjudicated by an independent central committee. Events include arterial rupture or dissection, uterine rupture, intestinal rupture and unexplained sudden death. The interim analysis occurs after 28 qualifying events and the final analysis after 46.

At June 30, 2026, 66 patients had been enrolled and three confirmed events had occurred, compared with 62 patients and two events at March 31. That low event count is both reassuring for enrolled individuals and problematic for a trial that needs events to read out. Event-driven studies can take much longer than calendar-based recruitment charts suggest. Completing enrollment does not automatically bring the analysis close if qualifying events remain rare. ClinicalTrials.gov currently estimates primary completion in March 2029 and study completion in April 2029, but those registry dates are planning estimates rather than company-guaranteed readout dates.

Zevra plans further FDA dialogue in the second half of 2026 to discuss whether the program can be accelerated. Possible acceleration is a catalyst, but it should not be assumed. FDA previously required a rigorous controlled trial, and any alternative must still support a reliable benefit-risk conclusion. Q2 supplied updated enrollment and event counts but no specific faster pathway or readout date. Celiprolol therefore remains meaningful but long-duration optionality.

Registry last updated August 24, 2025, checked September 7, 2026: recruiting, planned 150, estimated primary completion March 1, 2029 and overall April 1, 2029. This older registry must be read alongside the newer company Q2 count of 66 enrolled and three confirmed events. It is not a promised 2029 publication date.

ClinicalTrials.gov · DiSCOVER

17 OLPRUVA: Approved, Available and Commercially Marginal

OLPRUVA is a formulation of sodium phenylbutyrate approved as adjunctive therapy for chronic management of certain urea cycle disorders involving deficiencies of carbamyl phosphate synthetase, ornithine transcarbamylase or argininosuccinate synthetase in adults and children weighing at least 20 kilograms. The formulation was designed to improve palatability and portability relative to older sodium phenylbutyrate products.

The commercial reality has been weak. OLPRUVA produced only $0.8 million of net revenue in full-year 2025, $0.3 million in Q1 2026 and $0.2 million in Q2. The product competes with established nitrogen-scavenger therapies including RAVICTI or generic glycerol phenylbutyrate, BUPHENYL or generic sodium phenylbutyrate and PHEBURANE. In a rare market with established prescriber routines, a formulation advantage has not translated into a major franchise.

Zevra has reduced commercial emphasis and has discussed evaluating strategic alternatives. That is a sensible allocation decision if additional sales spending cannot produce attractive returns. OLPRUVA should therefore be treated as a small source of revenue and possible strategic monetization, not as a major bull-case pillar.

The asset also carries continuing obligations. Zevra owes a 10% royalty on U.S. OLPRUVA net sales, capped at $45 million, plus potential regulatory milestones. Former Acer holders can receive contingent value rights tied to specified OLPRUVA and celiprolol milestones. The contractual CVR maximum is much larger than the accounting fair value because the reported liability incorporates probability and discounting.

18 KP1077 and AZSTARYS: Why Old Zevra Profiles Are Wrong

Many financial-data pages still describe KP1077 as Zevra’s clinical sleep-disorder program and AZSTARYS as a continuing royalty asset. That description became stale in March 2026. Zevra sold its entire SDX portfolio, including AZSTARYS, KP1077 and related intellectual property, to Commave Therapeutics for $50 million in cash and settled the companies’ Delaware litigation.

The payment schedule was $25 million at signing, $20 million within ten business days and $5 million following delivery of specified records. Aquestive Therapeutics was entitled to 10% of SDX-related value, leaving Zevra with $45 million of net cash proceeds and Aquestive with $5 million. Zevra recorded a $43.3 million accounting gain in Q1 after transaction and accounting effects.

The former AZSTARYS agreement and its potential future milestones and royalties were terminated. Q1’s $1.1 million AZSTARYS-related revenue covered the pre-termination period and should not be annualized. In exchange for clean separation, Commave received a worldwide, fully paid, perpetual and irrevocable license to certain retained Zevra patents and know-how covering SDX.

The sale improved strategic focus but increased concentration. Zevra no longer has KP1077 as a second clinical program outside rare disease and no longer owns the future AZSTARYS royalty stream. The current pipeline is narrower, with MIPLYFFA and celiprolol carrying almost the entire operating story.

19 Financial Snapshot: Q2 Shows Positive Core Operations Without a Transaction Gain

Zevra reported Q2 2026 net revenue of $39.663 million, up 53.3% from $25.881 million a year earlier and 9.5% from Q1. MIPLYFFA U.S. net revenue represented $30.2 million, or about 76% of the total. Global EAP net reimbursement was $9.0 million, about 23%. Past-due AZSTARYS royalties and other reimbursements contributed $0.3 million, while OLPRUVA contributed $0.2 million.

Cost of product revenue was $1.525 million, excluding $0.316 million of intangible amortization. R&D expense was $4.486 million and SG&A was $16.559 million. Operating income reached $16.777 million. Unlike Q1, Q2 operating income did not depend on the $43.3 million SDX-sale gain; unlike Q2 2025, the current quarter did not include a PRV-sale gain, the OLPRUVA impairment or an inventory write-down.

GAAP net income was $8.752 million, or $0.14 per basic and diluted share, after a $6.408 million non-cash fair-value charge related to warrant and CVR liabilities and $4.042 million of income-tax expense. Zevra presented company-defined adjusted net income of $15.2 million, or $0.25 per diluted share. That non-GAAP measure helps isolate operations but should not be treated as audited recurring earnings.

Operating cash flow was positive $23.174 million for the first half of 2026, versus an $11.823 million outflow in the first half of 2025. The filing cautions that near-term operating cash flow could still be minimally positive or negative and that recent positivity is not guaranteed. A single profitable half-year should therefore not be converted mechanically into a permanent cash-generation rate.

20 Balance Sheet, Debt Repayment and Real Liquidity

At June 30, Zevra held $145.3 million in cash and equivalents, $76.2 million in current investments and $38.6 million in non-current investments, for total liquidity of $260.2 million. That was $23.4 million above the March 31 total. Long-term debt remained zero after the company repaid the prior facility in March and released all associated liens.

The liquidity increase reflects positive operating cash flow, warrant-exercise proceeds, the final Commave payment and other cash and investment movements. It should not be attributed to any one item without reconciling the complete cash-flow statement.

The debt payoff deserves precision. Zevra repaid approximately $63.1 million of principal including payment-in-kind interest, plus accrued cash interest, a final-payment premium, a make-whole or prepayment premium and legal fees. The total cash requirement was roughly $73.6 million. The SDX transaction produced $45 million of net proceeds to Zevra, so it economically offset a large portion of the payoff, but the debt was repaid one day before the asset-sale agreement became effective. It is therefore inaccurate to say that the sale proceeds literally funded the repayment at closing.

There are still non-debt liabilities. At June 30, Zevra reported a $13.2 million warrant liability, $28.1 million of current and non-current income-tax payable, $24.9 million of discount and rebate liabilities and an $18.6 million aggregate EAP clawback liability embedded within the relevant balance-sheet accounts. The company remains financially strong, but net cash should not be interpreted as if every dollar were distributable or available for repurchase.

Exact June liquidity bridge: cash $145.321M + current investments $76.249M + noncurrent investments $38.609M = $260.179M. H1 operating cash inflow $23.174M; Q2 net income $8.752M. H1 net income includes a $43.314M Commave gain, while the $148.325M PRV gain was in 2025; neither is recurring product revenue. Term debt is zero after March repayment, but total liabilities remain $85.060M, including tax, rebates and warrants.

SEC · Q2

21 Capital Structure and Dilution: Low Immediate Need Does Not Mean Zero Capacity

Zevra had 59.342 million common shares outstanding at June 30 and 59.384 million at July 31. The company also reported 7.427 million shares underlying outstanding equity-plan awards and 2.529 million shares underlying warrants. The company-defined fully diluted count was 69.298 million shares, 16.8% above basic outstanding shares.

An additional 7.777 million shares were available for future equity-plan issuance and 1.012 million for the employee stock purchase plan. Those reserved shares are not all outstanding awards and should not be counted as guaranteed dilution. They demonstrate authorization capacity, not a current live fully diluted share count.

Zevra’s June 2024 shelf registration permits up to $350 million of securities, with $75 million allocated to a Citizens JMP at-the-market program. No ATM shares had been sold through June 30, 2026. Warrant exercises generated $9.2 million during the first half, while basic shares increased 4.4% from year-end. The prior August 2024 public offering used part of the shelf, leaving substantial theoretical capacity subject to securities-law and filing conditions.

The strong cash balance and positive first-half operating cash flow reduce the probability of a financing driven by survival needs. However, Zevra has explicitly described business development as a future pipeline source. An acquisition or in-license could use cash, equity or both. Investors should therefore distinguish financing risk from capital-allocation dilution. The former appears low near term; the latter remains possible if management buys growth.

August 21 inducement grants: options for 92,200 shares to four new employees, vesting over four years. This is incremental potential dilution, not immediate issuance of all shares. The July 12, 2024 $75M ATM within the June 2024 shelf had no sales through June 30 and is not additional cash in the balance sheet.

IR · awards

22 Management and Governance: Execution Strength With a Medical Leadership Transition

Neil F. McFarlane serves as president, chief executive officer and a director. Joshua Schafer is chief commercial officer, Rahsaan W. Thompson is chief legal, secretary and compliance officer, and Justin Renz became chief financial officer in March 2026. The company’s leadership must now manage a rare combination of launch execution, European regulatory appeal, late-stage clinical development and potential business development.

Chief Medical Officer Adrian Quartel stepped down for personal reasons effective July 3, 2026. He will support Zevra as a consultant through December 31 while the company searches for a successor. The planned transition reduces immediate continuity risk, but the timing is not ideal: the company is preparing an EMA re-examination and expects FDA dialogue on DiSCOVER in the second half of 2026. The quality and timing of the next CMO appointment are therefore material governance items.

At the 2026 annual meeting, shareholders strongly supported a proposal to declassify the board, but it failed because it did not reach the charter-required threshold of more than two-thirds of all outstanding shares. The staggered board remains. This is not an operating catalyst, but it is relevant for governance-sensitive investors.

Recent insider filings showed sales under pre-established Rule 10b5-1 plans and compensation-related option or restricted-stock grants. CEO McFarlane and former CMO Quartel adopted trading plans in March. Adoption of a plan is not a sale and should not be treated as evidence of a hidden negative view. The better governance test is whether management communicates the European evidence problem transparently and avoids overpromising an accelerated celiprolol timeline.

23 Institutional Ownership, Short Interest and Analyst Expectations

Current dated market ownership and short-interest fields appear in section 05. Older proxy holdings and analyst target lists predate the CHMP setback and should not be represented as current consensus. StockTwits September 7: canonical sentiment 32/100 bearish, activity 31/100 low, 24,279 watchers; tagged messages 100% bullish are a separate selected sample. Neither measure changes the regulatory evidence.

24 Competitive Landscape: NPC, VEDS and Urea Cycle Disorders

NPC

MIPLYFFA’s closest direct product competitor is IntraBio’s AQNEURSA, approved by FDA on September 24, 2024, and authorized in Europe. AQNEURSA is a stand-alone levacetylleucine therapy for neurological manifestations of NPC in adults and pediatric patients weighing at least 15 kilograms. MIPLYFFA is approved with miglustat for patients aged two and older. The labels are different enough that use may be complementary or patient-specific rather than purely substitutive, but payer and prescriber competition is real.

VEDS

No FDA-approved disease-specific pharmacologic therapy currently defines the U.S. VEDS market. Patients receive cardiovascular risk management and other supportive or off-label care. Celiprolol is used in parts of Europe, giving Zevra real-world and clinical context, but U.S. approval depends on DiSCOVER or another FDA-accepted path. The absence of an approved therapy raises potential value if the trial succeeds but does not reduce the evidentiary standard.

Urea cycle disorders

OLPRUVA competes against established nitrogen-scavenger treatments including RAVICTI, generic glycerol phenylbutyrate, BUPHENYL, generic sodium phenylbutyrate and PHEBURANE. The product’s formulation and palatability advantages have not produced meaningful share, making commercial scale more difficult than the approval status alone suggests.

25 Bull Case: U.S. MIPLYFFA Becomes a Durable Rare-Disease Franchise

The constructive scenario begins with continued MIPLYFFA growth in the United States. New prescription enrollment forms remain steady, payer coverage expands beyond 69%, diagnosed-but-untreated patients convert and persistence remains high. Q2 and subsequent quarters demonstrate that the launch is not only pent-up demand from the easiest-to-find patients.

In Europe, Zevra keeps most EAP patients on treatment and reimbursement remains economically meaningful while re-examination proceeds. A successful re-examination would reopen a commercial population that management estimates at approximately 1,100 European NPC patients, with potentially higher diagnosis rates than in the United States. Even without immediate reversal, stable EAP access would protect a significant revenue stream.

Celiprolol adds a second leg if FDA dialogue produces a credible acceleration path or DiSCOVER enrollment and event accumulation improve. The large cash balance funds the program without forcing a dilutive financing and gives Zevra flexibility to add another rare-disease asset. Long-dated MIPLYFFA patent protection supports franchise durability.

In this scenario, the market begins valuing Zevra as an early commercial rare-disease company with two major assets rather than a one-product company recovering from a European setback.

26 Base Case: U.S. Growth Offsets Europe, but the Multiple Stays Discounted

The middle scenario assumes MIPLYFFA continues growing in the United States but at a more measured rate as the initial launch cohort matures. EAP revenue becomes less predictable after the CHMP opinion, with some countries maintaining access and others tightening reimbursement or new enrollment.

Re-examination remains pending into late 2026 or early 2027 and ultimately may or may not reverse the opinion. Investors apply little value to Europe until the final result. Celiprolol enrollment progresses, but event accumulation remains slow and no near-term readout can be dated.

The balance sheet absorbs these delays. Zevra remains able to fund operations and avoid a survival financing, but management must decide whether to preserve cash or pursue business development. The equity trades primarily on U.S. MIPLYFFA sales, net cash and shifting probabilities for Europe and celiprolol.

27 Bear Case: The Refusal Is Upheld and Launch Quality Weakens

The negative scenario begins with CHMP upholding the refusal. National expanded-access programs then shrink, reimbursements fall or clawback reserves increase. The loss is not merely theoretical future European sales; it affects a revenue stream that represented roughly 28% of Q1 company revenue.

In the United States, new patient starts slow after the initial diagnosed cohort, competition from AQNEURSA intensifies and payer friction keeps gross-to-net pressure high. MIPLYFFA remains a useful medicine but does not reach the revenue durability expected by pre-CHMP analysts.

Celiprolol fails to provide a near-term offset because DiSCOVER events accumulate too slowly or FDA declines to accelerate the program. OLPRUVA remains negligible. Management responds by licensing or acquiring another asset, using a meaningful portion of cash and possibly issuing equity through the shelf or ATM.

Under this scenario, Zevra’s cash balance limits immediate solvency risk but does not prevent valuation compression. Cash can reduce downside severity; it cannot replace commercial growth or clinical proof.

28 Risk Register: What Can Break the Thesis

29 What to Watch After Q2

Monitor MIPLYFFA growth and conversion of prescription forms, EAP reimbursement and country-specific access, the already-requested CHMP re-examination, DiSCOVER event accumulation, and allocation of cash. September investor conferences can update the narrative but are not regulatory decisions.

30 Corporate and Regulatory Timeline

31 Bottom Line

Zevra Therapeutics has a narrower pipeline than many old profiles imply, but it has a more substantial operating base than many small-cap biotech companies. MIPLYFFA is an approved U.S. product with meaningful revenue, celiprolol is a genuine Phase 3 rare-disease program, and the balance sheet provides time to respond to setbacks without immediately turning to the capital markets.

The July 2026 CHMP opinion is nevertheless a major negative. EMA questioned the reliability and robustness of the efficacy case and did not accept the miglustat subgroup as sufficient when the overall population failed to establish effectiveness. Re-examination is valuable, but it should be treated as a contested regulatory event rather than an administrative correction.

The Q2 report improved the first test: MIPLYFFA revenue accelerated sequentially, enrollment forms increased and core operations were profitable. The equity case still depends on three continuing tests. First, the U.S. launch must sustain growth after the initial cohort. Second, Zevra must preserve expanded-access economics and present a credible European response. Third, celiprolol must move from theoretical late-stage optionality toward a more predictable FDA pathway and event timeline.

That combination justifies a permanent Stock Hub. ZVRA is not a diversified platform and it is not a clean regulatory rebound. It is a concentrated commercial rare-disease company with strong liquidity, one proven launch, one high-risk European dispute and one potentially valuable but slow event-driven Phase 3 program.